Efficacy of pranlukast for nasal symptoms and physical activity in asthma children with moderate/severe allergic rhinitis

Efficacy of pranlukast for nasal symptoms and physical activity in asthma children with moderate/severe allergic rhinitis - Pranlukast for rhinitis and physical activity in children

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011408

Enrollment

Registered

2013-09-01

Start date

2013-09-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

leukotriene receptor antagonist, pranlukast antihistamine, fexofenadine

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Eligible patients fulfill the following conditions; 1) House dust mite-sensitized perennial allergic rhinitis with moderate/severe symptom of nasal obstruction based on Practical guideline for the management of allergic rhinitis in Japan 2013 2) Well-controlled bronchial asthma

Exclusion criteria

Exclusion criteria: 1) leukotriene receptor antagonists within 2 weeks before study entry 2) antihistamines within 2 weeks before study entry 3) nasal corticosteroids and/or nasal antihistamines within 2 weeks before study entry 4) systemic corticosteroids within 4 weeks before study entry 5) chronic diseases other than allergy 6) disability or dysfunction of physical activity 7) patients whom a study physician considers inappropriate for the study

Design outcomes

Primary

Measure	Time frame
symptom score of allergic rhinitis	—

Secondary

Measure	Time frame
physical activity evaluated by using an accelerometer, Lifecorder EX	—

Countries

Japan

Contacts

Public ContactMizuho Nagao

Mie National Hospital Department of Clinical Research

nagaomizuho@mie-m.hosp.go.jp059-232-2531

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026